Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow. Despite advances in chemotherapy and radiotherapy, first-line therapy of AML results in long-term diseasefree survival in only 20-30% of patients. Selective approaches targeting cytotoxic agents to these cells might offer a promising avenue for the specific elimination of residual disease following classical therapy. One of the currently explored experimental approaches involves the viral vector-mediated transduction of such residual acute myeloid leukemic cells with immunomodulatory genes. 1 This has been described for a number of viral vector systems including lentiviruses, retroviruses, adenoviruses, adeno-associated virus and HSV-1 amplicons. One of the major advantages in the context of immunomodulatory gene transfer is the preclinical observation of antileukemic bystander effects, suggesting that not every cell needs to be transduced, as was shown for instance for B7.1, interleukin-12, tumor necrosis factor-a and granulocyte-macrophage colony-stimulating factor. 1 In addition, many viral vectors may themselves have immunostimulatory properties, which upon infection of the cancer cell may lead to increased antigen presentation and stimulation of an anticancer immune response. However, specific targeting of viral vectors to leukemic cells remains a significant obstacle. In addition, circulating virus-specific antibodies normally act to neutralize virus infections and are thereby likely to counteract viral vector-based therapies. However, in addition to using the common receptor-dependent virus entry mechanisms, some viruses can, under certainusually pathological -conditions, also use antiviral antibodies for their entry into target cells. This mechanism, known as Fc-receptor-mediated antibody-dependent enhancement of viral infection, was proposed by Halstead and Porterfield and colleagues (for review, see Takada and Kawaoka 2 ). The concept is that virus-antibody complexes can bind to cells expressing Fc receptors (such as cells of the immune system, including macrophages, monocytes, B-cells, neutrophils and granulocytes) through interaction between the Fc portion of the antibody and the Fc receptor on the cell surface, providing a bridge that mediates the attachment of viruses to those cells. Several human Fc receptors exist, each exhibiting a different immunoglobulin (Ig) Fc tail specificity. The high affinity receptor FcgRI efficiently binds to human IgG1; in addition, it crossreacts with mouse IgG2a. 3 FcgRI is highly expressed on AML cells of type M4 and M5 morphology (according to the French-American-British classification system) but is absent on pluripotent stem cells and on CD34 þ hematopoietic progenitor cells. Thus, the FcgRI may represent an appropriate AML target receptor for cytotoxic agents considering that the normal FcgRI-positive immune effector cells will repopulate after termination of the FcgRItargeted therapy.
We have shown recently that coronaviruses can be specifically retargeted to selected cells using various types of bispecific adapters including single-chain antibodies. [4] [5] [6] This prompted us to explore the use of normal virus-specific antibodies as adapters for targeting viral vectors to FcgRI molecules as expressed on cells of certain types of AML. As a model vector, we used a mouse hepatitis coronavirus (MHV) encoding the firefly luciferase (MHV-EFLM). 7 This virus normally infects only murine cells through the specific interaction of its spike (S) protein with the cellular receptor murine CEACAM1a. We first checked whether the virus could establish infection of human cells via the FcgRI by using a chimeric protein composed of the S-binding N-domain of mCEACAM1a fused to a human IgG1 Fc tail (N-CEACAM-Fc). 8 We inoculated THP-1 cells, which are human AML cells lacking mCEACAM1a expression but expressing high amounts of FcgRI, with MHV-EFLM at different multiplicities of infection (MOIs) in the absence or presence of different concentrations of N-CEACAM-Fc protein. After 20 h, the cells were lysed and luciferase activity was measured. Figure 1 shows that N-CEACAM-Fc was able to mediate infection of the otherwise refractory THP-1 cells in a manner that depended both on the dose of the virus and on the presence and concentration of the adapter. At higher concentrations, N-CEACAM-Fc becomes increasingly virus neutralizing.
Next, we analyzed a number of anti-MHV monoclonal antibodies (MAbs) for their ability to redirect MHV-EFLM infection to the FcgRI-positive THP-1 cells. We used a set of available antibodies with known MHV protein specificity and IgG subclass 9 The combined results demonstrate that antibodies can direct a viral vector, in this case MHV-EFLM, specifically to the FcgRI on human leukemic cells. The efficiency of targeting obviously depends on the specific features of the antibodies, particularly on their Ig-subclass (human IgG1 or murine IgG2a). How the efficiency depends on the viral epitope recognized by a particular antibody is unclear and will be specific for any given virus. Its importance is illustrated nicely by the anti-MHV MAbs A1.4 and A3.10, which are both of IgG2a subclass and which both recognize a (different) epitope in the S1 part of the MHV S protein, but of which only the latter effects FcgRI-mediated MHV infection (Figure 2 ). 
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Besides coronaviruses, various other viruses have been described to use Fc receptors as an alternative entry pathway; examples include HIV, HSV-1, poliovirus, yellow fever virus and influenza A virus. 8 Therefore, the use of antibodies to target viral vectors to AML cells may also be applicable to other viral vector systems. Clearly, not every MAb will be able to target a particular virus to the FcgRI. However, for several of these viruses specific 1q21-25 is one of the 'hotspots' of chromosomal alteration, including duplications and translocations, frequently detected in hematological malignancies. As a consequence of these aberrations, genes may become deregulated or fusion genes may be formed and interfere with the normal programs of cell growth and differentiation. We report here on a patient with t (1;2)(q21;q37) occurring in acute myeloid leukemia (AML) with antecedent myelodysplastic syndrome (MDS).
The patient was a 71-year-old male (case #30 in SIH-MDS series) who was diagnosed as having progressive MDS.
Hematologic data were as follows: red blood cells 2.87 Â 10 12 /l, hemoglobin 83 g/l, white blood cells 14.9 Â 10 9 / l and a platelet count of 34 Â 10 9 /l. Bone marrow (BM) biopsy: the marrow was hypercellular. The M/E ratio was normal. Myeloblasts and promyelocytes were increased to 28.5%, consistent with myelodysplastic syndrome progression to acute myeloid leukemia. The patient was treated with cyclophosphamide, vincristine, cytosine arabinoside and prednisone (COAP) combination therapy. Cytogenetic analysis with R-banding technique on unstimulated BM cells at admission revealed t(1;2) (q21;q37) chromosome translocation in 10 metaphases among 11 analyzed (90%) (Figure 1b) . Chromosomal translocation t(1;2) (q21;q37) was also confirmed by chromosomal painting (CP) using whole CP probes for chromosome 1 
